News

IEO launches Cosmos II, a new action plan against lung cancer

Milan, May 8, 2012

“A combined attack against lung cancer has started at the European Institute of Oncology: a revolutionary examination based on circulating micro-RNA and low dose CT scan for early diagnosis of lung cancer. It represents the beginning of a new era in the diagnosis of lung cancer."

The Cosmos II has been launched following the promising results of the first IEO’s sponsored trial Cosmos (Continuous Observation of SMOking Subjects), to improve early diagnosis of lung cancer considered today as the most important life-saving tool. This is a multicenter Italian study, coordinated by IEO created to identify an optimal personalized protocol for early diagnosis in people subject to high risk of lung cancer (heavy smokers).

Starting from next 15th of July 10,000 heavy smokers or former smokers will be recruited throughout Italy (other clinical center are participating to the study: Florence, Rome, Pescara, L'Aquila and Palermo). The volunteers will be subjected to low-dose CT scan and blood test for the detection of biological markers of disease (microRNAs, miRNAs).

Download the PDFpdf Press_release_cosmosII_eng.pdf

IDDN, research and industry together for new drugs

Milan, 2 May 2012

Angelini, Dompè, the European Institute of Oncology (IEO), the Italian Institute of Technology (IIT), Recordati and Rottapharm/Madaus has signed an agreement to create a centralized chemistry collection with the aim to identify new biologically active molecules for the development of new drugs.

This public-private partnership project, unique in Europe, was established under the Italian Drug Discovery Network (IDDN) initiative, launched by pharmaceutical companies and research institutes to promote a fruitful interaction between private and public and to join knowledge and resources of each promoter of IDDN giving new boost to innovation in the treatment of human disease.

----------------------------------------------------------------------------------------------------------------------

Angelini, Dompe', l'Istituto Europeo di Oncologia (Ieo), l'Istituto Italiano di Tecnologia (Iit), Recordati e Rottapharm|Madaus hanno sottoscritto un accordo per creare una collezione chimica centralizzata con l'obiettivo di individuare nuove molecole biologicamente attive per lo sviluppo di nuovi farmaci.

Questo progetto di collaborazione pubblico-privato, unico nel suo genere in Europa, nasce nell'ambito dell'iniziativa Italian Drug Discovery Network (IDDN), voluta dalle aziende e dagli istituti di ricerca partecipanti per favorire una piu' proficua interazione tra realta' private e pubbliche operanti nel settore farmaceutico e della ricerca scientifica e punta a unire capacita', conoscenze e risorse di ciascun promotore dell'Iddn e dare nuovo impulso all'innovazione nella cura delle patologie umane.

Per maggiori dettagli segui il link

A collaboration between Heinz and IEO gives birth to a new generation of infant food

Milan, 12 April 2012

The European Institute of Oncology and H.J. Heinz company, owner of Plasmon®, get together in order to promote children’s health.

An important research project was started in Milan between H.J. Heinz company, owner of Plasmon®, and the European Institute of Oncology through the technology transfer company TTFactor; it focuses on the study of functional foods and molecules able to promote the correct development of the infant immune system so as to improve his defenses and reduce the risks of immune diseases such as allergies, inflammatory bowel disease and celiac disease, and potentially tumors.

The study is performed by Maria Rescigno’s team, internationally recognized immunologist who is one of the main experts in mucosal immunity and anti-tumor immunotherapy. In particular, she stood out in the correlation between intestinal immunity, overall health and use of probiotics, live bacteria capable of positively influencing human health.

Click to download the full text: ENG pdf press_release_heinz_eng.pdf or ITA pdf comunicato_stampa_Heinz_ita.pdf

Farmaci antitumore, intesa tra Nerviano e IEO

22 Marzo 2012

Sancito un importante Protocollo di Intesa tra l'Istituto Europeo di Oncologie (IEO) e Nerviano Medical Sciences, firmato a Palazzo Lombardia, alla presenza, tra gli altri, del presidente Roberto Formigoni, dell'assessore regionale alla Sanità, Luciano Bresciani, del presidente della Fondazione regionale per la ricerca biomedica e del Nerviano Medical Sciences, Alberto Sciumè e del direttore scientifico dell'IEO, Umberto Veronesi

Link all'articolo integrale Farmaci antitumore, intesa tra Nerviano e IEO [articolo]

TTFactor (la societa' di trasferimento tecnologico di IFOM e IEO)

TTFactor signs a Research Agreement with OncoMed Pharmaceuticals Inc. for Advancing Novel Cancer Therapies through IEO Scientific Expertise

Milan, December 9, 2011

TTFactor srl (the technology transfer company of IFOM and IEO) today announced a research collaboration with OncoMed Pharmaceuticals Inc., a company developing novel therapeutics that target cancer stem cells or tumor-initiating cells, to test OncoMed’s clinical candidates in a new generation of tumor models developed at the “Molecular Medicine for Care Program” of IEO, headed by Prof. Pier Paolo Di Fiore.

Click to download the full-text pdf Press_Release_ENG.pdf

TTFactor signs an interinstitutional agreement with Universita' degli Studi di Milano

Milano, October 24, 2011

TTFactor, IEO and IFOM have signed an interistitutional agreement with Milan University concerning joint IP management. This agreement is aimed at facilitating technology transfer process, from bench to bedside, of their joint research results.

pdf Press Release in Italian, 540.03 Kb

Page 1 of 2

Start
Prev
1
2
Next
End